Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
First they need to submit Filings. SEC process after that is slow.
Excellent CEO interview here:
That's excellent!
Entrex receives #investor #capital committment for $PIPE. #entrex #finance #stocks #carbonoffset #energy
https://twitter.com/EntrexInc/status/1375509672170426371?s=20
UNSS LONG & STRONG
According to the YouTube reviewer who will be interviewing the CEO next week, they've ramped up Covid-19 revenue at a rate of $3-5M per month. We should learn much more from CEO next week. Also they've applied to sell tests in the UK. They will add a Lab in Toronto and upgrade their Vancouver Lab .
Load up before the next run folks! Fins any day now.
$DRNK gonna get high Haha
Same! Cheapy loading zone here with tons of catalysts on the way.
$DRNK GO!!!
Yup, could be a good one. Still fairly unknown.
All good things but something stinks with this ticker. I'm mostly concerned with OTCX on the ASK often associated with institutional selling. I'll be watching from the sideline. GL
Good to see.
Back to Dimeland this week very possible!
UNSS GO!!!!
Been following this one for a while, but finally took a position on the dip at 0.107. $35M - That is great news!
$ILUS GO!
Haha, all good! ;)
Welcome. Yes, same!
To clarify, it's the SEC that has little to gain from the CE removal (per Watkins' comment) - my apologies if my post wasn't clear. I agree 100%, UNSS (Entrex) and we shareholders have much to gain from the CE removal.
Let's hope it happens sooner than later!
UNSS GO!
Watkins email update: UNSS working hard to advance the business, not at the pace he would like but moving forwards on many (all) fronts.
Regarding CE: Fins "not holding up CE... think OTC is overwhelmed... while also in Covid shutdown.
They have little to gain from removal.. just a process to them.
That said... I still believe all is in process.. and ready for removal."
Hold on to your shares people. It will be well worth it!
UNSS Long & Strong
Added some 0.151s. A true gift IMO!
REOS and UNSS will shine very soon!
OTCX raised the Ask. Good sign!
Same. Hidden gem here!
QNTA GO!
$QNTA Cancer drug Clinical results only 30M Float with tiny 30M Float and huge news, low PPS!
https://finance.yahoo.com/news/medolife-rx-announces-pre-clinical-130000576.html
Medolife Rx Announces Pre-Clinical Results on Drug Candidate Escozine Showing Efficacy in Eliminating Cell Lines in Ovarian and Bladder Cancer
Quanta, Inc.
Tue, March 23, 2021, 6:00 AM
BURBANK, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today clinical trial results conducted on its lead drug candidate Escozine® where the drug eradicated in vitro bladder (SCaBER) and ovarian (OVCAR-3 and IGR-OV1) cancer cell lines when administered for 24 hours.
The study was conducted at one of the most prestigious academic research facilities in the United States. The goal of the study was to assess the viability of human bladder and ovarian cancer cells treated with Escozine®, the Company’s polarized drug candidate derived from a small molecular peptide found in scorpions. It examined the effects of both polarized and non-polarized versions of the drug on the viability of cell walls, finding that only the polarized version had a significant effect on eliminating the cell lines in all three cancers. This highlights not only the potential of Escozine® as a treatment for cancer, but the increased efficacy and bioavailability of the drug through the polarization methodology unique to Medolife Rx. Cell lines are commonly used in in vitro model systems in many drug discovery research programs. They retain most of the genetic properties of the cancer of origin and provide researchers with an indefinite source of biological material for experimental purposes (source). This study was especially significant in that Escozine® eradicated the cell lines completely, furthering the hypothesis that the drug could eliminate cancer cells in humans completely as well.
Very thin move up! Momentum should be picking up soon.
UNSS LONG & STRONG
Agreed! Lots of catalysts.
DRNK GO!
$SCRN ScreenPro Security Ltd. - Excellent DD on this highly undervalued company:
Video Link: https://www.youtube.com/watch?v=jauV7J02tXo
Merger News: https://www.newsfilecorp.com/release/76205
ScreenPro and Compel Capital Enter into Definitive Agreement, Complete RTO, and Start Trading
March 5, 2021
Toronto, Ontario--(Newsfile Corp. - March 5, 2021) - ScreenPro Security Ltd. (CSE: SCRN) ("ScreenPro" or the "Company"), is pleased to announce that it has entered into a definitive agreement dated February 28, 2021 (the "Definitive Agreement") with Compel Capital Inc. ("Compel") in respect of a proposed reverse take-over transaction (the "Proposed Transaction"). The Proposed Transaction is an arm's length transaction and upon successful completion of the Proposed Transaction, it is anticipated that the resulting entity (the "Resulting Issuer") will focus primarily on the business of ScreenPro under the name "ScreenPro Security Ltd." or such other name determined by the parties.
About ScreenPro
ScreenPro is a private company existing under the laws of British Columbia and is based with offices both in Toronto and Vancouver, British Columbia. There are currently 60,816,994 common shares in the capital of ScreenPro (the "ScreenPro Shares") and 607,674 common share purchase warrants outstanding (the "ScreenPro Warrants"). Pursuant to the terms of the Definitive Agreement, ScreenPro will complete a share split (the "Share Split") on the basis of 1 pre-Share Split ScreenPro Share for every 4.68858594500271 post-Share Split ScreenPro Shares prior to the completion of the Proposed Transaction. At which time, ScreenPro will consolidate its share count as agreed to in the terms of the RTO with Compel post the listing on the CSE.
ScreenPro provides turnkey coronavirus screening solutions to the private sector. ScreenPro's unique access to multiple manufacturers of high quality South Korean test kits and its strategic partnership with Canvas Labs in Vancouver and Integrated Explorations in Ontario. This platform allows ScreenPro to be a nationwide provider of a full service testing solutions across Canada. In addition to providing test kits, ScreenPro has access to high quality PPE to ensure that its clients are protected in all aspects of their testing needs.
Proposed Transaction
Pursuant to the Definitive Agreement, the parties plan to complete a three-cornered amalgamation whereby a newly incorporated wholly-owned subsidiary of Compel ("Compel Subco") will amalgamate with ScreenPro, and Compel will acquire all of the issued and outstanding ScreenPro Shares. The shareholders of ScreenPro will receive common shares in the capital of Compel (the "Compel Shares") in exchange for their ScreenPro Shares, resulting in a reverse takeover of Compel by the ScreenPro shareholders. The corporation resulting from the amalgamation of Compel Subco and ScreenPro will be wholly-owned by the Resulting Issuer.
It is intended that Compel Shares will be issued to holders of ScreenPro Shares on the basis of one (1) ScreenPro Share for every one (1) ScreenPro Share (the "Exchange Ratio"), resulting in the issuance of 285,145,703 Compel Shares to the shareholders of ScreenPro. Upon closing of the Proposed Transaction, the ScreenPro Warrants will cease to represent a right to acquire ScreenPro Shares and will provide the holder the right to acquire Compel Shares, all in accordance with the adjustment provisions provided in the certificates representing the ScreenPro Warrants, subject to the Exchange Ratio.
The Definitive Agreement also contemplates other material conditions precedent to the closing of the Proposed Transaction (the "Closing") including compliance with all applicable regulatory requirements and receipt of all necessary approvals being obtained. The Canadian Securities Exchange (the "Exchange") conditionally approved the listing of the Compel Shares on January 20, 2021.
There can be no assurance that the Proposed Transaction will be completed as proposed, or at all. There is no assurance that the Resulting Issuer will be able to satisfy the listing requirements set out in the Exchange's conditional approval letter dated January 20, 2021.
The Closing will involve, among others, the following steps:
receipt of all shareholder and regulatory approvals relating to the Proposed Transaction, including, without limitation, the approval of the Exchange (or such other exchange on which application to list the Compel Shares may be made); and
each of the parties shall have executed, delivered and performed their respective covenants as outlined in the Amalgamation Agreement, and all representations and warranties of each party contained in the Amalgamation Agreement shall be true and correct at the time of Closing.
The Compel Shares to be issued pursuant to the Proposed Transaction will be issued pursuant to exemptions from the prospectus requirements of applicable securities legislation. Certain of the Compel Shares issuable pursuant to the Proposed Transaction may be subject to the escrow requirements of the Exchange and to hold periods as required by applicable securities laws.
The Resulting Issuer - Summary of Proposed Directors
It is currently anticipated that certain of the current officers and directors of the Company will resign from their respective positions with the Company.
Following the Closing, the board of directors of the Resulting Issuer will consist the following four (4) directors, each of whom will be a nominee of ScreenPro and these individuals will represent the directors proposed to be elected at the annual and special meeting of Compel scheduled on March 15, 2021.
John McMullen
John McMullen began his career in financial management in 1998, he has worked in the Canadian capital markets for over 20 years. Throughout his career he has seeded and launched numerous investment funds, private and public corporations raising over 50 million dollars globally to date. Mr. McMullen has advised and enabled companies to grow from his ability to connect and expand opportunities on a global platform. From 2014 to 2016, he was an investment banker with Strategis Capital in Toronto, Ontario and was both the CEO of LGC Capital from 2017 and became President in 2019 under the new name Elixxer Ltd. He resigned in July of 2020 and shortly thereafter focused on working with Datametrex and ultimately taking on the role of CEO at ScreenPro. John McMullen holds a Bachelor of Arts from the University of Western Ontario.
Youngcho Lee
Youngcho Lee has BA in Accounting and MBA from Hanyang University in South Korea. He worked in accounting, finance, and auditing department at LG Group headquarters, overseeing all subsidiaries including LG Electronics, LG Construction, and LG Chemicals. He was responsible for management and consulting projects, specializing in M&A and restructuring. After leaving LG, he founded and operated an educational institution for 15 years in Vancouver. After a successful exit from education industry, he started mobile communications and IT mobile platform businesses in Vancouver and Toronto. He has extensive experience in management, restructuring, financial management, and sales and marketing strategy.
James Hyland
Jamie brings more than 25 years of experience in the public markets as a financial and marketing consultant, a corporate founder and manager of numerous early-stage public and private businesses. His industry expertise includes hospitality, publishing, financial services, technology, mining, alternative energy and healthcare appliances. Mr. Hyland has an extensive network of contacts with the financial community including fund managers, industry analysts and media, throughout North America, the United Kingdom and continental Europe. Mr. Hyland has also worked with a major mining and resource publication based in Vancouver BC. Mr. Hyland earned a Bachelor of Commerce in Entrepreneurial Management from Royal Roads University of Victoria, BC. Canada.
Richard Yoon
Richard is currently the CEO of ZTE Canada responsible for ZTE's business in Canada. Richard joined ZTE Canada in April 2015 as Director of Business Development, with responsibilities for developing new business opportunities in Canada. Within short time frame, Richard made significant contribution to the business growth in Canada and now serves as CEO of ZTE Canada. Richard is a strategic thinker, team oriented and results driven leader with a track record of innovation and success in the business world. Prior to joining ZTE Canada, Richard has worked in management positions for several other OEM such as Huawei and Palm and has also held management positions with Canadian Telecom carriers such as TELUS, Bell and Clearnet. Richard holds a Bachelor of Arts, Mathematics for Commerce from York University, Toronto, Canada granted in 1990.
Disclosure and Caution
Further details about the Proposed Transaction, financial information regarding ScreenPro and the Resulting Issuer will be provided in the disclosure document to be prepared and filed in respect of the Proposed Transaction.
Investors are cautioned that, except as disclosed in the disclosure document, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon.
All information provided in this press release relating to ScreenPro has been provided by management of ScreenPro and has not been independently verified by management of the Company.
For further information please contact:
John McMullen
Phone: 1-416-803-0698
Email: john@screenprosecurity.com
Forward Looking Statements
Certain statements contained in this news release may constitute forward-looking information, including statements relating to the completion of the Proposed Transaction, the proposed business of the Resulting Issuer, the completion of the Share Split and subsequent Consolidation, the proposed directors and officers of the Resulting Issuer, shareholder, director and regulatory approvals, and future press releases and disclosure. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The actual results of the Company, ScreenPro or the Resulting Issuer could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company and ScreenPro operate, prevailing economic conditions, changes to the Company or ScreenPro's strategic growth plans, and other factors, many of which are beyond the control of the Company and ScreenPro. Each of the Company and ScreenPro believe that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company and ScreenPro's expectations as of the date hereof, and is subject to change after such date. Each of the Company and ScreenPro disclaim any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/76205
Do your own DD - AIMHO
Agreed! Especially with Float so locked up.
UNSS GO!!
DRNK GO!!!!!!!!!!
NOHO HangoverDefense
@NOHOdrink
Happy Monday DRNK! Financials in final stage of accounting and legal review. We will update when submitted to OTC. BOD has resolved to cancel C class Preferred and reduce authorized common from 25 billion to 15 billion.
Yup, word is getting out. Thanks again for the heads up. MMBF let's go!!!
$1.25 is a nice target!
Still needs to be posted. Every piece helps and Watkins is working hard to close some deals.
This is not a momentum stock, it's a long term hold. CE removal will be nice but there is so much more tooth's gem as you know. :)
UNSS LONG & STRONG
Wow 400K Bid!
More OTCX fake trades.
UNSS ENTREX TWEET!: Entrex #Oil and #Gas Market negotiates transaction with $REOS #entrex #oilandgas #offsets #market
https://twitter.com/EntrexInc/status/1374025452671561728?s=20
New tweet!
Entrex #Oil and #Gas Market negotiates transaction with $REOS #entrex #oilandgas #offsets #market
https://twitter.com/EntrexInc/status/1374025452671561728
UNSS LONG & STRONG
30 day count down is over - LET'S GO!!! Come on SEC, remove that CE status so UNSS can start the journey to DOLLARLAND!!!
UNSS GO!!!!!
Thank you so much for the detailed response. I never knew it had a top gainers page. You would think iHub would make that an easier page to access, but anyway at least they have one.
Congrats and thanks again. That's an awesome win!
Congrats Garyst! May I ask how you found this ticker early?
HUGE NEWS! Empower Clinics Announces Receipt of Over $12,000,000 From Exercise of Warrants, Receives Full MDEL Status from Health Canada, Finalizes Lease Agreements for Initial Canadian Health Centers and Completes Lease for KAI Lab Expansion
Friday, March 19, 2021 3:30 AM
Share this article now
Topic: Company Update
Warrant Proceeds and Continued Business Development on Multiple Fronts Positions Empower for Continued and Rapid Growth in 2021
VANCOUVER, BC / ACCESSWIRE / March 19, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to provide a comprehensive corporate update with respect to the following matters:
RECEIPT OF OVER $12,000,000 FROM THE EXERCISE OF WARRANTS
Empower is pleased to announce the receipt of in excess of $12,000,000 from the exercise of warrants up to March 18, 2021, representing an increase of approximately $1,500,000 since the Company's announcement on March 4, 2021 when the Company announced the receipt of approximately $10,500,000.
The receipt of these warrant proceeds, along with the Company's expectations of generating continued significant revenue from its KAI Medical Laboratory, as well as, anticipated significant revenue from its national Canadian clinic launches and test kit sales over the next 12 months, provides Empower with the war chest necessary for continued rapid expansion in each of its divisions.
Steven McAuley, Chairman and CEO of Empower stated "Theodore Roosevelt said credit belongs to…who is actually in the arena, whose face is marred by dust and sweat…, I can attest that I am in the arena, our team members are in the arena, all focused, working hard for our shareholders, ensuring we continue to grow and reach new heights." Mr. McAuley goes on to say "The company has never looked better, has never been more stable than today, has a great balance sheet and has clear vision for the future. Our leadership team, our entire team share a collective vision of growth, we care about patients, we are focused on technology, we understand the importance of what we are doing."
RECEIPT OF FULL MEDICAL DEVICE ESTABLISHMENT LICENCE (MDEL) APPROVAL STRENGTHENS ABILITY TO SELL AND DISTRIBUTE KAI SALIVA AT-HOME COVID-19 RT-PCR TEST IN CANADA AND OTHER APPROVED TESTING PRODUCTS GOING FORWARD
Empower's KAI Medical COVID-19 Saliva Test ("KAI Saliva") is an FDA EUA and Health Canada authorized at-home Saliva COVID-19 RT-PCR Test. KAI Saliva provides travelers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into Canada or arriving in other countries that have similar executive travel orders.
On January 21, 2021 Empower announced the filing of an MDEL for the purposes of importing, distributing and selling KAI Saliva which has experienced immediate success upon its launch on December 15, 2020 in the United States, with an initial soft launch order of 5,000 units and an order for the next 25,000 KAI Saliva PCR Test Kits with a sales value of approximately $5.5M.
On March 8, 2021 Empower announced it anticipates an order for the next 50,000 KAI Saliva test kits to prepare for demand.
Our MDEL can now be found on the Government of Canada MDEL 'Live Listings' page.
"We all have an urgent requirement for a home-based, self-administered COVID-19 saliva test kit that can help open up the economy and facilitate travel that meets the requirements of the executive travel orders." said Steven McAuley, Chairman & CEO. "As a result of receiving full MDEL status, Empower is engaged in meaningful discussions with several potential distribution partners across Canada. We fully expect KAI Saliva to enjoy the kind of success it is achieving in the United States."
KAI Saliva can provide major airlines, cruise lines and the tourism sector with the ability to provide solutions for travelers by making a KAI Saliva purchase part of the ticketing purchase, the check-in process, in a kiosk, or on an e-commerce website.
NEGOTIATED LEASE AGREEMENTS FOR FIRST THREE HEALTH CENTRE LOCATIONS WITH BUILD OUT TO COMMENCE IN Q2 2021
On February 25, 2021 Empower announced the locations of the first three integrated health centers in Ontario, with each location anticipated to generate on average approximately $3,000,000 in annualized revenue, as follows:
1) Etobicoke, Ontario Approximately 2,700 sq.ft
2) London, Ontario Approximately 3,100 sq.ft
3) Etobicoke, Ontario Approximately 2,900 sq.ft
Empower is now advancing to the build-out phase with first completions and openings anticipated for 2Q 2021. Advanced discussions are currently underway on multiple additional locations as the Company advances the rollout of its national clinic expansion strategy.
Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location.
When each location is fully operational, Empower anticipates it can generate $2,560,000 - 3,600,000 in annual revenue per location.
COMPLETION OF LEASE AGREEMENT FOR KAI MEDICAL LABORATORY EXPANSION
KAI Medical Laboratory ("KAI LAB"), a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company's COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI LAB experienced significant growth in its first quarter under Empower (October 2020 - December 2020), with Q4 COVID-19 test units exceeding 6,000, far surpassing the 1,300 total units prior to acquisition.
Furthermore, on March 8, 2021, Empower announced KAI LAB had achieved the following significant milestones in 2021:
1. Each of January and February 2021 were record months for specimen collection and processing, with February delivering sequential growth of 27% over January 2021.
2. Exceeded single day specimen processing of 1,000 + units in February.
3. As a result of record months year to date 2021, the KAI LAB annual revenue run rate is now exceeding $10,000,000 with meaningful positive cash flow
As a result of this continued rapid growth in 2021, Empower announced "Doubling KAI Medical Laboratory In Anticipation Of Test Volumes By End Of Q1." The Company then revised this planned expansion upwards on February 16th when it announced "KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1."
KAI LAB has now completed the lease amendment with the landlord to take over the neighboring tenants' space to triple the size of KAI LAB. Tenant's improvements are set to commence immediately and before the end of March 2021. The expansion work will enable KAI LAB to hire additional staff across a wide array of roles, all to improve operational efficiency and to meet anticipated demand over the coming weeks and quarters.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT EMPOWER:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across the US and Canada. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
CEO
CONTACTS:
Steven McAuley CEO
s.mcauley@empowerclinics.com
604-789-2146
Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
416-671-5617
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE: Empower Clinics Inc.
http://www.digitaljournal.com/pr/5011572
The slow trade volume today proves multiple OTCX trades yesterday almost every second were completely fake to induce action and scare investors out of their shares.
Congrats to your future self Lol
UNSS = Life changer!!
To induce action or scare others out of their shares at lower prices IMO.